- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00485693
Dose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty (TKA)
A Phase 2 Multicenter, Randomized, Double-blind, Parallel-group, Active-control, Dose-ranging Study to Evaluate the Safety, Efficacy, and Comparative Systemic Bioavailability of a Single Administration of SKY0402 Via Local Infiltration for Prolonged Postoperative Analgesia in Subjects Undergoing Total Knee Arthroplasty.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35209
- West Alabama Research, Inc.
-
-
California
-
Davis, California, Forenede Stater, 95616
- California Clinical Research, Inc.
-
Laguna Hills, California, Forenede Stater, 92653
- Accurate Clinical Trials, Inc.
-
-
New York
-
New York, New York, Forenede Stater, 10019
- St. Luke's Roosevelt Hospital
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43220
- The Ohio State University Medical Center
-
-
Texas
-
Lubbock, Texas, Forenede Stater, 79430
- Texas Tech University Health Science Center
-
-
-
-
-
Brno, Tjekkiet, 66250
- Úrazová nemocnice Brno
-
Kladno, Tjekkiet, 1548
- Regional Hospital Kladno
-
Třebíč, Tjekkiet, 67401
- The Hospital Trebic
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male or female, greater than or equal to 18 and less than or equal to 75 years of age at the Screening Visit.
- Female subjects only: Postmenopausal, surgically sterile, or willing to use acceptable means of contraception for at least 30 days after surgery including any of the following: hormonal contraceptives (e.g., oral, injectable, implantable starting at least 30 days before study drug administration), effective double-barrier methods (e.g., condoms with spermicide), intrauterine device, lifestyle with a personal choice of abstinence, nonheterosexual lifestyle, or a strictly monogamous relationship with a partner who has had a vasectomy.
- Scheduled to undergo primary unilateral total knee arthroplasty (TKA) under general anesthesia.
- American Society of Anesthesiology (ASA) Physical Class 1-3.
- Able and willing to comply with all study visits and procedures.
- Able to speak, read, and understand the language of the Informed Consent, study questionnaires, and other instruments used for collecting subject-reported outcomes, in order to enable accurate and appropriate responses to pain scales and other required study assessments.
- Willing and capable of providing written informed consent.
Exclusion Criteria:
- Pregnancy, nursing, or planning to become pregnant during the study or within one month after dosing.
Use of any of the following medications within the times specified before surgery:
- Long-acting opioid medication within 3 days.
- Any opioid medication within 24 hours.
- Concurrent, painful, physical condition or concurrent surgery that may require analgesic treatment in the postoperative period for pain that is not strictly related to the surgical site administered study treatment, and which may confound the postoperative assessments (e.g., significant pain from other joints, chronic neuropathic pain, concurrent contralateral TKA, concurrent foot surgery, etc.).
- Body weight less than 50 kilograms (110 pounds) or morbid obesity.
- Contraindication to any of the pain-control agents planned for postoperative use (e.g., acetaminophen, morphine, oxycodone, ketorolac).
- Contraindication to epinephrine, such as concurrent administration of monoamine oxidase (MAO) inhibitors or antidepressants of amitriptyline or imipramine types, conditions where the production or exacerbation of tachycardia could prove fatal (e.g., poorly controlled thyrotoxicosis or severe heart disease), or any other pathological conditions that might be aggravated by the effects of epinephrine.
- Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
- History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
- Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator, may interfere with study assessments or compliance.
- Current or historical evidence of any clinically significant disease or condition, especially cardiovascular or neurological conditions that, in the opinion of the Investigator, may increase the risk of surgery or complicate the subject's postoperative course.
Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicate an increased vulnerability to study drugs and procedures, and expose the subject to an unreasonable risk as a result of participating in this clinical trial, such as: debilitating diseases, acute illnesses, hypotension, partial or complete conduction block, impaired cardiac function, untreated hypertension, advanced arteriosclerotic heart disease, cerebral vascular insufficiency, pre-existing abnormal neurological or neuromuscular disease (e.g., epilepsy, myasthenia gravis), advanced liver disease, severe renal impairment, advanced diabetes comorbid conditions associated with an immunocompromised status, such as blood dyscrasias, HIV/AIDS, or recent chemotherapy.
In addition, the subject will be ineligible to receive study drug if he or she meets the following criteria during surgery:
- Any clinically significant event or condition uncovered during surgery(e.g., excessive bleeding), which occurs before study drug administration, that might render the subject medically unstable or complicate the subject's postoperative course.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Bupivacaine HCl
Bupivacaine HCl (Marcaine 0.25% with epinephrine 1:200,000)
|
150 mg Bupivacaine HCl
Andre navne:
|
Andet: SKY0402
SKY0402 at various dosage levels.
Single administration.
|
600 mg SKY0402 (study drug)
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores Through Postoperative Day 4
Tidsramme: 0 to 96 hours
|
The subject's pain intensity was to be assessed with activity (NRS-A) after actively flexing the involved knee to the maximum flexion point possible.
The subject was asked to respond to the following question: "On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain did you have while bending your knee?"
|
0 to 96 hours
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Number of Participants With Adverse Events or Serious Adverse Events Through 30 Days
Tidsramme: Up to 30 days
|
Up to 30 days
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Postoperative komplikationer
- Smerte
- Neurologiske manifestationer
- Smerter, postoperativ
- Lægemidlers fysiologiske virkninger
- Adrenerge midler
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Depressive midler til centralnervesystemet
- Autonome agenter
- Agenter fra det perifere nervesystem
- Sensoriske systemagenter
- Bedøvelsesmidler
- Adrenerge alfa-agonister
- Adrenerge agonister
- Bedøvelsesmidler, lokale
- Bronkodilatatorer
- Anti-astmatiske midler
- Respiratoriske midler
- Adrenerge beta-agonister
- Sympatomimetika
- Vasokonstriktormidler
- Mydriatics
- Bupivacain
- Adrenalin
Andre undersøgelses-id-numre
- SKY0402C208
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Postoperativ smerte
-
Wake Forest University Health SciencesRekruttering
-
University of California, San DiegoJohns Hopkins University; United States Department of Defense; The Cleveland... og andre samarbejdspartnereTilmelding efter invitationKirurgisk amputation af nedre ekstremiteter | Post-amputation Phantom Limb PainForenede Stater
-
Brugmann University HospitalTrukket tilbagePhantom Limb Pain (PLP) | Primær/sekundær arhyperalgesiBelgien
-
Quiropraxia y EquilibrioUniversidad Nacional Andres BelloAfsluttetMyofascial Trigger Point Pain (MTrP)Chile
-
East Carolina UniversityTrukket tilbage
-
Quiropraxia y EquilibrioIkke rekrutterer endnuMyofascial Trigger Point Pain (MTrP)Chile
-
Rijnstate HospitalSaluda Medical Pty LtdTilmelding efter invitationPolyneuropatier | Kronisk smertesyndrom | Multi Focal Pain | Mislykket nakkekirurgi syndromHolland
-
Oslo University HospitalUniversity of Oslo; Fysiofondet; Oslo Metropolitan UniversityRekrutteringGluteal tendinopati | Trochanterisk bursitis | Lateral hoftesmerter | GTPS - Greater Trochanteric Pain SyndromeNorge
-
University of KentuckyDonJoy OrthopedicsAfsluttetPostoperativ Quadriceps Svaghed | Postoperativ Quadriceps-hæmning | Overholdelse af postoperativ behandling | Postoperativ underekstremitetsfunktionForenede Stater
-
Ospedale Misericordia e DolceUkendtPostoperativ smerte | Thyroidektomi | Postoperativ kvalme og opkast | Postoperativ stemmefunktionItalien
Kliniske forsøg med Bupivacaine HCl
-
Mayo ClinicAfsluttetSmerter, postoperativ | Brachial Plexus BlokForenede Stater
-
Pacira Pharmaceuticals, IncAfsluttetPostoperativ smertebehandlingForenede Stater
-
University of Texas Southwestern Medical CenterAfsluttetSkuldersmerterForenede Stater
-
Istanbul UniversityAfsluttetSmerter, postoperativKalkun
-
InnocollPremier Research Group plcAfsluttetHernioplastikForenede Stater
-
Ataturk UniversityAfsluttetBrystkræft | Postoperativ smerteKalkun
-
DurectNycomedAfsluttetPostoperativ smerteØstrig, Tyskland, Letland, Polen, Sverige
-
DurectNycomedAfsluttetPostoperativ smerteFrankrig, Tyskland, Ungarn, Letland, Sverige, Det Forenede Kongerige
-
The Cleveland ClinicPacira Pharmaceuticals, IncAfsluttetSmerter, postoperativ | MammaplastikForenede Stater
-
InnocollPremier Research Group plcRekrutteringPostoperativ smerte | LyskebrokForenede Stater